Brian Hilberdink is Senior Vice President, Commercial Diabetes, at Novo Nordisk Inc. since April 15, 2019. He is responsible for leading commercial operations for the diabetes portfolio in the US including sales, brand strategies and initiatives to enhance growth and patient reach.
Mr. Hilberdink is an
accomplished pharmaceutical executive with over 20 years of global
and domestic experience at Novo Nordisk developing and executing
strategy. Before joining Novo Nordisk Inc. in 2019, he was President
of Novo Nordisk Canada. As President he significantly increased
investment in Canada, launched several innovative products in the
therapy areas of diabetes, obesity and hemophilia, and the company
was recognized as one of the country’s top 100 employers.
Prior to his work at Novo
Nordisk Canada, Mr. Hilberdink was a Corporate Vice President in
Global Marketing for Novo Nordisk A/S in Copenhagen, Denmark,
leading the launch of the company’s insulin portfolio. He also has
experience working at Novo Nordisk in the US, where, from 2003 –
2006, he led several commercial teams during a period of significant
growth and investment.
Mr. Hilberdink holds a
bachelor’s degree from the Arts & Science faculty at Queen’s
University in Canada, and has completed extensive executive
education at multiple universities.